William Zuo Biography and Net Worth

Insider of Athenex

William has served as President of Polymed Therapeutics since 1995 and Chairman of Chongqing Taihao Pharmaceutical since 2012. William specializes in the development, manufacturing, global sale and marketing of various complex Active Pharmaceutical Ingredients (“API”), especially the injectable Oncology APIs. William was the CEO of the Fibrocell Science (NYSE: FCSC) companies in Asia from 2010 to 2013. He introduced the first US FDA approved cell therapeutics product, LaViv, to the Asia market. William has been responsible for the building of numerous cGMP facilities in China and has extensive experience in dealing with the Food and Drug Administration in both China and the United States.

William received his PhD in Nanotechnology from Rice University where he worked extensively with Dr. Richard Smalley, the late Nobel Prize Scholar. William also has a Masters degrees in Chemical Engineering and Applied Mathematics from Rice University.

What is William Wei Zuo's net worth?: The estimated net worth of William Wei Zuo is at least $0.00 as of March 4th, 2021. Mr. Zuo owns 142,883 shares of Athenex stock worth more than $0 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Zuo may own. Learn More about William Wei Zuo's net worth.
How do I contact William Wei Zuo?: The corporate mailing address for Mr. Zuo and other Athenex executives is 1001 Main Street Suite 600, Buffalo NY, 14203. Athenex can also be reached via phone at (716) 427-2950 and via email at [email protected]. Learn More on William Wei Zuo's contact information.
Has William Wei Zuo been buying or selling shares of Athenex?: William Wei Zuo has not been actively trading shares of Athenex during the last ninety days. Most recently, William Wei Zuo sold 419,931 shares of the business's stock in a transaction on Thursday, March 4th. The shares were sold at an average price of $4.52, for a transaction totalling $1,898,088.12. Following the completion of the sale, the insider now directly owns 142,883 shares of the company's stock, valued at $645,831.16. Learn More on William Wei Zuo's trading history.
Who are Athenex's active insiders?: Athenex's insider roster includes Kim Campbell (Director), Rudolf Kwan (EVP), Johnson Lau (CEO), Jinn Wu (Director), and William Zuo (Insider). Learn More on Athenex's active insiders.

William Wei Zuo Insider Trading History at Athenex

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/4/2021	Sell	419,931	$4.52	$1,898,088.12	142,883
3/25/2019	Buy	1,000	$12.47	$12,470.00	1,118,777

William Wei Zuo Buying and Selling Activity at Athenex

Athenex Company Overview

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Today's Range

Now: N/A

50 Day Range

MA: $0.95

$0.20

$1.52

2 Week Range

Now: N/A

Volume

1,880,200 shs

Average Volume

194,316 shs

Market Capitalization

$1.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.